| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Medical Buyouts Dominate Last Week's News
Posted on 05/21/2007 07:28:20 | Link | Post Comment
by Hisham S. Ayoub, DMD
BioHealth Investor.com
It seems that the medical and biotech buyout frenzy of late 2006 continued well into last week with major deals dominating the week's headlines.
Mylan Laboratories (MYL) announced that it will buy Merck KgA's (MRK) generic drug unit for $6.6 billion! How expensive is this price? Well, consider that Mylan's market cap was $5 billion. The company had to issue about $2 billion in stock and related debt just to complete the transaction. Wall Street was obviously not too positive on the price paid by Mylan as the company's stock fell 12% on the day.
Cardinal Health (CAH) offered $1.5 billion to acquire Viasys Healthcare (VAS). This to me looks like a great pick up by Cardinal, since Viasys's array of ventilators and diagnostic instruments complement its line of hospital supplies. Cardinal Health paid the $1.5 billion all in cash, and Viasys should add to its bottom line almost immediately.
Biosite (BSTE) finally agreed to be acquired by Inverness Medical Innovations (IMA) for $92.50 a share, after Beckman Coulter (BEC) refused to increase its own offer of $90 a share. This bidding battle between Inverness and Beckman Coulter pushed Biosite's share price up by more than %66.
Bausch & Lomb (BOL), a leading contact lens maker, had agreed to be taken over by private equity firm Warburg Pincus for $4.7 billion, a %6 premium to the prior day's closing price. While some believed it to be a pretty low offer, I personally think that with Bausch & Lomb's many current legal issues with its recalled contact lens solutions not many other suitors would have paid any more.
While not as large of a deal, but a healthcare related deal none-the-less, is the purchase of IOMED (IOX) by privately-held orthopedic device company ReAble for $22 million. This shows that the interest in biomedical firms is strong no matter the size.
Source: BioHealth Investor.com
RELATED READING:
- Inverness Bids Even Higher for Biosite
- Biotech Buy-Outs Continue, Solexa latest Pickup
_____________________
BioHealth Investor.com
It seems that the medical and biotech buyout frenzy of late 2006 continued well into last week with major deals dominating the week's headlines.
Mylan Laboratories (MYL) announced that it will buy Merck KgA's (MRK) generic drug unit for $6.6 billion! How expensive is this price? Well, consider that Mylan's market cap was $5 billion. The company had to issue about $2 billion in stock and related debt just to complete the transaction. Wall Street was obviously not too positive on the price paid by Mylan as the company's stock fell 12% on the day.
Cardinal Health (CAH) offered $1.5 billion to acquire Viasys Healthcare (VAS). This to me looks like a great pick up by Cardinal, since Viasys's array of ventilators and diagnostic instruments complement its line of hospital supplies. Cardinal Health paid the $1.5 billion all in cash, and Viasys should add to its bottom line almost immediately.
Biosite (BSTE) finally agreed to be acquired by Inverness Medical Innovations (IMA) for $92.50 a share, after Beckman Coulter (BEC) refused to increase its own offer of $90 a share. This bidding battle between Inverness and Beckman Coulter pushed Biosite's share price up by more than %66.
Bausch & Lomb (BOL), a leading contact lens maker, had agreed to be taken over by private equity firm Warburg Pincus for $4.7 billion, a %6 premium to the prior day's closing price. While some believed it to be a pretty low offer, I personally think that with Bausch & Lomb's many current legal issues with its recalled contact lens solutions not many other suitors would have paid any more.
While not as large of a deal, but a healthcare related deal none-the-less, is the purchase of IOMED (IOX) by privately-held orthopedic device company ReAble for $22 million. This shows that the interest in biomedical firms is strong no matter the size.
Source: BioHealth Investor.com
RELATED READING:
- Inverness Bids Even Higher for Biosite
- Biotech Buy-Outs Continue, Solexa latest Pickup
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Tue Jul 15, 2008 08:25AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
Morpheus Trading - Mon Jul 14, 2008 02:18AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home